[{"uuid": "11571e62-f31b-3a03-8fda-7e98e55df42f", "title": "4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/4dmt-announces-corporate-webcast-review-130000552.html", "providerPublishTime": 1738155600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_dIhMI1e0EGfp7ki87crfg--~B/aD01NjA7dz0xOTc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 1979, "height": 560, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_n8h2Cu3PEtjKZMWiZsGeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "5ad1f146-aed6-3cec-bd0b-2598e1b9e931", "title": "Top US Penny Stocks To Watch In January 2025", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/top-us-penny-stocks-watch-170455036.html", "providerPublishTime": 1737738295, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eZ0FiSKCVDYnTK6X1bRieQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CMCM", "FDMT", "HYLN"]}, {"uuid": "f8ae479f-71ce-30da-b3aa-881d45432f0c", "title": "BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/bmo-capital-downgrades-4d-molecular-122336920.html", "providerPublishTime": 1736771016, "type": "STORY", "relatedTickers": ["FDMT"]}, {"uuid": "c5611352-755f-3c01-9068-6d560f2e22d5", "title": "4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/4d-molecular-therapeutics-focus-pipeline-135356155.html", "providerPublishTime": 1736517236, "type": "STORY", "relatedTickers": ["FDMT"]}, {"uuid": "b59b5ac3-93d3-3c90-bb81-b603c89a4bd5", "title": "4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/4dmt-focuses-pipeline-prioritize-4d-130000777.html", "providerPublishTime": 1736514000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_dIhMI1e0EGfp7ki87crfg--~B/aD01NjA7dz0xOTc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 1979, "height": 560, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_n8h2Cu3PEtjKZMWiZsGeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "673ad5e9-ebfd-30f8-affd-3f7e08cbb0ac", "title": "4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/4dmt-announces-positive-interim-data-130000938.html", "providerPublishTime": 1736514000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_dIhMI1e0EGfp7ki87crfg--~B/aD01NjA7dz0xOTc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 1979, "height": 560, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_n8h2Cu3PEtjKZMWiZsGeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "ee32be13-6698-398b-8715-671d5e6132f0", "title": "4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/4d-molecular-therapeutics-inc-fdmt-222007213.html", "providerPublishTime": 1731536407, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/eeFsK50..hTdRBoBNDEyoA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b", "width": 900, "height": 711, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/U.GeD2pq81ETtKFpwtAvMA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "1b802742-c678-35fd-ac5f-7ee992b567e3", "title": "4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/4d-molecular-therapeutics-inc-fdmt-115157129.html", "providerPublishTime": 1732621917, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/JTmnNgqP_gi0IgVpzfCJiw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/440469665224be487e36d212c06532e9", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/PAtx6xz2xP_698aZjVt5Mg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/440469665224be487e36d212c06532e9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "54f5d908-df6a-38c1-8be8-1aa6fb93363e", "title": "4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/4dmt-announces-landmark-publication-4d-130000217.html", "providerPublishTime": 1734354000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_dIhMI1e0EGfp7ki87crfg--~B/aD01NjA7dz0xOTc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 1979, "height": 560, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_n8h2Cu3PEtjKZMWiZsGeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "24481f81-9e60-3047-b9b5-a42316127618", "title": "4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/4dmt-participate-upcoming-investor-conferences-130000438.html", "providerPublishTime": 1731589200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_dIhMI1e0EGfp7ki87crfg--~B/aD01NjA7dz0xOTc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 1979, "height": 560, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_n8h2Cu3PEtjKZMWiZsGeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "fd40b410-fa7d-369d-8249-bb0ab506ae04", "title": "4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights\u00a0and Expected Upcoming Milestones", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/4dmt-reports-third-quarter-2024-210500247.html", "providerPublishTime": 1731531900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_dIhMI1e0EGfp7ki87crfg--~B/aD01NjA7dz0xOTc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 1979, "height": 560, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_n8h2Cu3PEtjKZMWiZsGeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6822d10ab37bc11df0216f4bd39730bf", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FDMT"]}, {"uuid": "0701eb9a-ed46-3de9-a567-e725fdf96036", "title": "RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/rbc-trims-price-target-4d-115939563.html", "providerPublishTime": 1731585579, "type": "STORY", "relatedTickers": ["FDMT"]}, {"uuid": "f8473033-8fb1-3ec7-acab-ef04a156ac0a", "title": "ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-reports-124004917.html", "providerPublishTime": 1731501604, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/lCdXNO5h4hmjtS7ps0voGA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SPRY"]}, {"uuid": "476fee65-986f-3f2d-a877-c9271b426401", "title": "Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/heron-therapeutics-hrtx-reports-q3-141003423.html", "providerPublishTime": 1731420603, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/8iH7sUYRxbYanfZU7fLgpA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["HRTX"]}, {"uuid": "19690ac1-d2f5-30cf-b54b-d2eea8b0a006", "title": "Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/nektar-therapeutics-nktr-reports-q3-224008550.html", "providerPublishTime": 1731019208, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/tAIISbFeyqAamZ0jMaEx_g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["NKTR"]}]